Continued Semaglutide 2.4 mg Once Weekly Improved Health Related Quality of Life in the STEP 4 Trial

被引：0
|
作者：
Sharma, Arya
Meincke, Henrik
Jensen, Camilla
Kushner, Robert
Pedersen, Sue
Rubino, Domenica
Tran, Marie
Wharton, Sean
Bjorner, Jakob
机构：
来源：
OBESITY | 2021年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
014
引用
收藏
页码：9 / 10
页数：2
相关论文
共 50 条
  • [21] Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg
    Kelly, Aaron S.
    Arslanian, Silva
    Hesse, Dan
    Iversen, Aske Thorn
    Koerner, Antje
    Schmidt, Signe
    Sorrig, Rasmus
    Weghuber, Daniel
    Jastreboff, Ania M.
    OBESITY, 2023, 31 (08) : 2139 - 2149
  • [22] Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
    Frias, Juan P.
    Deenadayalan, Srikanth
    Erichsen, Lars
    Knop, Filip K.
    Lingvay, Ildiko
    Macura, Stanislava
    Mathieu, Chantal
    Pedersen, Sue
    Davies, Melanie
    LANCET, 2023, 402 (10403): : 720 - 730
  • [23] Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
    Loomba, Rohit
    Abdelmalek, Manal F.
    Armstrong, Matthew
    Jara, Maximilian
    Kjaer, Mette
    Krarup, Niels
    Lawitz, Eric
    Ratziu, Vlad
    Sanyal, Arun
    Schattenberg, Joern
    Newsome, Philip N.
    JOURNAL OF HEPATOLOGY, 2022, 77 : S10 - S10
  • [24] Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
    Sandhu, Hera
    Xu, Weiwei
    Olivieri, Anamaria-Vera
    Lubker, Christopher
    Smith, Inger
    Antavalis, Vasileios
    ADVANCES IN THERAPY, 2023, 40 (03) : 1282 - 1291
  • [25] Semaglutide 2.4 mg once weekly reduces appetite, reduces energy intake, and improves control of eating in subjects with obesity
    Batterham, Rachel
    Breitschaft, Astrid
    Friedrichsen, Martin
    Morgan, Nigel
    Skovgaard, Dorthe
    Tadayon, Sayeh
    Wizert, Alicja
    OBESITY SURGERY, 2021, 31 (SUPPL 1) : S15 - S16
  • [26] Semaglutide 2.4 mg once weekly reduces appetite, reduces energy intake, and improves control of eating in subjects with obesity
    Skovgaard, D.
    Breitschaft, A.
    Wizert, A.
    Tadayon, S.
    Friedrichsen, M.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S266 - S267
  • [27] The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
    Friedrichsen, Martin
    Breitschaft, Astrid
    Tadayon, Sayeh
    Wizert, Alicja
    Skovgaard, Dorthe
    DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 754 - 762
  • [28] Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
    Hera Sandhu
    Weiwei Xu
    Anamaria-Vera Olivieri
    Christopher Lübker
    Inger Smith
    Vasileios Antavalis
    Advances in Therapy, 2023, 40 : 1282 - 1291
  • [29] Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial
    Romero-Gomez, Manuel
    Armstrong, Matthew J.
    Funuyet-Salas, Jesus
    Mangla, Kamal Kant
    Ladelund, Steen
    Sejling, Anne-Sophie
    Shrestha, Ichhya
    Sanyal, Arun J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (04) : 395 - 403
  • [30] IMPROVEMENT OF THE 10-YEAR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK WITH ONCE-WEEKLY SEMAGLUTIDE 2.4 MG IN ADULTS WITH OVERWEIGHT OR OBESITY - POST-HOC ANALYSIS OF THE STEP 1 TRIAL
    Verma, Subodh
    Bhatta, Meena
    Davies, Melanie
    Deanfield, John
    Garvey, Tim
    Kushner, Robert
    Rubino, Domenica M.
    Khalid, Usman
    Zeuthen, Niels
    Kosiborod, Mikhail
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1606 - 1606
12345